About Us
Our Technology
Our Pipeline
Our News
More
November 15, 2018
PsiOxus Therapeutics to Collaborate with the Parker Institute for Cancer Immunotherapy
December 12, 2017
PsiOxus Therapeutics Receives $15 Million Milestone Payment as Armed Oncolytic Virus Licensed to Bristol-Myers Squibb Achieves CTA
August 16, 2017
PsiOxus Therapeutics Announce Two New Board Appointments: Strengthens US Presence
June 13, 2017
PsiOxus Therapeutics Expands operations in both Oxford, UK and Philadelphia, USA
December 20, 2016
Bristol-Myers Squibb Signs Exclusive Worldwide License Agreement with PsiOxus Therapeutics for NG-348, an “Armed” Oncolytic Virus to Address Solid Tumors
November 15, 2016
PsiOxus Therapeutics Licenses Immunotherapeutic Delivery Technology ‘Polymap
September 16, 2016
PsiOxus Therapeutics Announce Executive Team Reorganization with Two New C Level Appointments in the US
June 30, 2016
Bristol-Myers Squibb and PsiOxus Therapeutics Announce Immuno-Oncology Clinical Collaboration to Evaluate the Combination of Opdivo and Enadenotucirev
March 10, 2016
PsiOxus Therapeutics Initiates Combination of Paclitaxel with Oncolytic Virus Enadenotucirev in Ovarian Cancer Study
January 7, 2016
PsiOxus Therapeutics Appoints Dr Paolo Paoletti as Chairman of the Board
